IDT Biologika, a contract development and manufacturing organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses, and Exothera S.A., a CDMO specializing in the industrialization of vaccine and gene therapy processes, are collaborating to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focusing on Modified Vaccinia Ankara (MVA) virus as a first example for IDT’s broad range of vector technologies.   Ex...